Matinas BioPharma Holdings (MTNB) EBITDA Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly EBITDA Margin of 854.23% for Q2 2023, down 29685.0% year-over-year from N/an in Q2 2022, and up 42.65% quarter-over-quarter from 1489.6% in Q1 2023.
Matinas BioPharma Holdings (MTNB) EBITDA Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported EBITDA Margin for 8 consecutive years, with 854.23% the latest figure, recorded in Q2 2023.
- In Q2 2023, EBITDA Margin fell 29685.0% year-over-year to 854.23%; the TTM figure through Dec 2023 stood at 2168.43% (down 139729.0% YoY), while the FY2023 annual figure was 2168.43%, down 139710.0% from the prior year.
- EBITDA Margin rose to 854.23% in Q2 2023 per MTNB's latest filing, from 1489.6% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2016293.39% in Q4 2021 and bottomed at 19059.52% in Q1 2021.
- Historically, EBITDA Margin has averaged 199274.87% across 5 years, with a median of 705.81% in 2023.
- Annual changes were most pronounced in 2021 — EBITDA Margin soared 200596620 bps — and 2022, when it plunged 201680892 bps.
- Matinas BioPharma Holdings' EBITDA Margin stood at 5033.49% in 2019, then surged by 305 bps to 10327.19% in 2020, then surged by 19424 bps to 2016293.39% in 2021, then tumbled by 100 bps to 515.52% in 2022, then tumbled by 66 bps to 854.23% in 2023.
- Business Quant data shows MTNB's EBITDA Margin at 854.23% in Q2 2023, 1489.6% in Q1 2023, and 515.52% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -854.23% |
| Mar 31, 2023 | -1,489.60% |
| Dec 31, 2022 | -515.52% |
| Sep 30, 2022 | -513.83% |
| Jun 30, 2022 | -557.38% |
| Dec 31, 2021 | 2,016,293.39% |
| Mar 31, 2021 | -19,059.52% |
| Dec 31, 2020 | 10,327.19% |
| Sep 30, 2020 | -5,848.30% |
| Jun 30, 2019 | -5,033.49% |
| Jun 30, 2018 | -3,791.13% |
| Mar 31, 2018 | -13,764.74% |
| Dec 31, 2017 | -10,311.72% |
| Sep 30, 2017 | -7,589.85% |
| Jun 30, 2017 | -8,854.73% |
| Mar 31, 2017 | -29,976.78% |
| Sep 30, 2015 | -3,606.48% |
| Jun 30, 2015 | -3,119.21% |
| Mar 31, 2015 | -4,456.62% |